Larson Financial Group’s Seres Therapeutics MCRB Stock Holding History

Larson Financial Group’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$39	Buy	+5	New	+$38	﹤0.01%	3693
2025 Q1	–	Sell	-12	Closed	-$195	–	3158
2024 Q4	$195	Hold	12	–	–	﹤0.01%	2449
2024 Q3	$222	Hold	12	–	–	﹤0.01%	2338
2024 Q2	$170	Hold	12	–	–	﹤0.01%	2116
2024 Q1	$182	Hold	12	–	–	﹤0.01%	1648
2023 Q4	$329	Hold	12	–	–	﹤0.01%	1615
2023 Q3	$559	Hold	12	–	–	﹤0.01%	1566
2023 Q2	$1.13K	Hold	12	–	–	﹤0.01%	1348
2023 Q1	$1.33K	Hold	12	–	–	﹤0.01%	1309
2022 Q4	$1.32K	Hold	12	–	–	﹤0.01%	1255
2022 Q3	$2K	Buy	+12	New	+$1.23K	﹤0.01%	1125

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Larson Financial Group's MCRB Position: Q2 2026 in Review

Larson Financial Group opened a new position in Seres Therapeutics (MCRB) in Q2 2026: 5 shares worth $39. The stake represents ﹤0.01% of the portfolio and ranks #3693 among its holdings. This is a return to the name: Larson Financial Group previously reported a position in MCRB as recently as Q4 2024.

Larson Financial Group first reported a position in MCRB in Q3 2022 and has held it in 11 quarters since. The position peaked at $2K in Q3 2022. 35 funds tracked by Wall St. Rank hold MCRB as of Q2 2026.

Larson Financial Group held 5 shares of Seres Therapeutics worth $39 as of Q2 2026.
Seres Therapeutics was a new Larson Financial Group position in Q2 2026.
Seres Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3693 holding.
Larson Financial Group first reported a position in Seres Therapeutics in Q3 2022 and has held it in 11 quarters since.
Larson Financial Group's Seres Therapeutics position peaked at $2K in Q3 2022.
35 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.